Aligos Therapeutics Inc. has described programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.
Liver fibrosis still lacks effective therapy; hepatic stellate cells (HSCs) are the primary fibrogenic cell type activated during liver injury. To date, almost half of the drugs used for liver treatment are natural product derivatives.
Kano Therapeutics Inc. announced it has secured $5 million in seed funding, bringing its total funding to date to $7.1 million. The company plans to use the funding to begin internal pipeline development of ex vivo genetic medicines based on kilobase gene insertion, expand its existing therapeutic collaborations to initiate externally driven preclinical programs, and scale its production capacity.
Esculetin, also known as 6,7-dihydroxycoumarin, is a coumarin-derived phytochemical that has shown effects against ischemic stroke. Additionally, chemokine-like factor 1 (CKLF1) has been revealed in previous findings to be a target for stroke when using coumarin-derived compounds. The effects of esculetin and the potential involvement of CKLF1 were tested in photothrombotic stroke in mice.
Piplartine, also called piperlongumine, had protective effects against hearing loss induced by aminoglycoside antibiotics in zebrafish and mouse models of kanamycin-induced hair cell loss. Kanamycin is a member of the aminoglycosides, a group of antibiotics that have broad-spectrum activity against gram-negative bacteria, including multidrug resistant strains.
A strategy inspired by deficient HIV replication could be used as a treatment to reduce viral load in patients living with HIV and help control the pandemic of the retrovirus. Scientists from the University of California San Francisco want to use HIV against itself by using a parasitic version of the pathogen.
China’s National Medical Products Administration has cleared Luye Pharma Group Ltd.’s new schizophrenia candidate LY-03020 to enter phase I trials in China. Independently developed by Shanghai-based Luye, the new chemical entity is a dual agonist that targets both the trace amine-associated receptor 1 and the 5-HT2C receptor and is intended to treat schizophrenia and Alzheimer’s disease psychosis.
Beijing Primegene Therapeutics Co. Ltd. has identified azacycloalkane compounds acting as rho kinase 1 (ROCK1; p160-ROCK) and/or rho-associated protein kinase 2 (ROCK 2) inhibitors reported to be useful for the treatment of asthma, cancer, insulin resistance, neurodegeneration, osteoporosis and renal failure.
Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has patented compounds acting as cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.
RSS
